ZBH:NYE-Zimmer Biomet Holdings, Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 147.01

Change

+1.78 (+1.23)%

Market Cap

USD 29.87B

Volume

0.69M

Average Target Price

USD 153.97 (+4.73%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Market Stats

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-12-11 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

+0.35 (+0.41%)

USD149.54B 45.96 21.19
MDT Medtronic plc

+0.68 (+0.61%)

USD148.84B 31.54 17.48
SNN Smith & Nephew plc

+0.46 (+1.04%)

USD19.65B 27.84 15.22
NVRO Nevro Corp

-1.40 (-1.28%)

USD3.40B N/A -37.58
ITGR Integer Holdings Corporation

+1.45 (+1.88%)

USD2.59B 22.95 12.66
BIO Bio-Rad Laboratories, Inc

-2.06 (-0.58%)

USD1.84B 28.35 27.34
BIO-B Bio-Rad Laboratories, Inc

N/A

USD1.82B 27.47 26.47
INSP Inspire Medical Systems, Inc

-1.32 (-1.81%)

USD1.74B N/A -52.51
GMED Globus Medical, Inc

+0.02 (+0.04%)

USD1.36B 39.49 24.11
PEN Penumbra, Inc

-1.81 (-1.14%)

USD1.24B 131.85 107.05

ETFs Containing ZBH

Symbol Name Weight Mer Price(Change) Market Cap
WELL:LSE HAN-GINS Indxx Healthcare.. 4.44 % 0.00 %

N/A

USD2.41M
MOAT:LSE VanEck Vectors Morningsta.. 2.64 % 0.00 %

-0.01 (-0.01%)

USD0.14B
WMW ELEMENTS Linked to the Mo.. 2.61 % 0.75 %

N/A

USD0.03B
GMVM:XETRA VanEck Vectors Morningsta.. 2.55 % 0.00 %

-0.06 (-0.17%)

USD0.16B
GOAT VanEck Vectors Morningsta.. 2.11 % 0.00 %

+0.15 (+0.50%)

USD6.12M
JKI iShares Morningstar Mid-C.. 1.54 % 0.30 %

+0.31 (+0.19%)

USD0.49B
DRFU:CA 0.94 % 0.57 %

N/A

N/A
IWS iShares Russell Mid-Cap V.. 0.63 % 0.24 %

+0.08 (+0.09%)

USD11.56B
DRFG:CA Desjardins RI Global Mult.. 0.60 % 0.00 %

-0.12 (-0.56%)

USD4.13M

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.74% 63% D 88% B+
Dividend Return 0.69% 17% F 10% F
Total Return 42.43% 63% D 87% B+
Trailing 12 Months  
Capital Gain 31.25% 63% D 86% B
Dividend Return 0.86% 17% F 11% F
Total Return 32.10% 63% D 85% B
Trailing 5 Years  
Capital Gain 29.82% 14% F 69% D+
Dividend Return 4.15% 43% F 13% F
Total Return 33.97% 14% F 59% F
Average Annual (5 Year Horizon)  
Capital Gain 4.08% 21% F 62% D-
Dividend Return 0.82% 43% F 19% F
Total Return 4.91% 21% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 12.58% 79% C+ 61% D-
Risk Adjusted Return 38.98% 32% F 49% F
Market Capitalization 29.87B 92% A- 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.10 93% A 65% D
Price/Book Ratio 2.47 68% D+ 34% F
Price / Cash Flow Ratio 17.09 54% F 24% F
EV/EBITDA 15.95 46% F 27% F
Management Effectiveness  
Return on Equity -0.76% 48% F 23% F
Return on Invested Capital 6.55% 62% D- 51% F
Return on Assets 3.51% 62% D- 61% D-
Debt to Equity Ratio 74.67% 24% F 48% F
Technical Ratios  
Short Ratio 2.00 69% D+ 57% F
Short Percent 0.93% 80% B- 88% B+
Beta 1.16 31% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.